Angiogenesis
- Cat.No. Product Name Information
-
B1408
CNX-774
CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.
-
A8677
SLIGKV-NH2
Protease-activated receptor 2 (PAR2) agonist (Ki = 9.64 μM and IC50 = 10.4 μM).
-
A8676
2-Furoyl-LIGRLO-amide
Potent and selective PAR2 receptor agonist (pD2 = 7.0). Causes a dose-dependent relaxation of murine femoral arteries.
-
A8675
TRAP-6
Peptide fragment (residues 42-47) of protease-activated receptor 1 (PAR1) that acts as a PAR1 agonist.
-
A8674
PAR 4 (1-6)
N-terminal fragment of protease-activated receptor 4 (PAR4) that acts as a PAR4 agonist (EC50 ~ 100 μM). Induces platelet aggregation and annexin V activation with no effect on clotting time.
-
A8673
LRGILS-NH2
Reversed amino acid sequence control peptide for SLIGRL-NH2, a protease-activated receptor-2 (PAR2) agonist that facilitates gastrointestinal transit in vivo.
-
A8672
RLLFT-NH2
Reversed amino acid sequence control peptide for TFLLR-NH2, a PAR1 selective agonist that significantly increases nociceptive threshold.
-
A8671
VKGILS-NH2
Reversed amino acid sequence control peptide for SLIGKV-NH2, a protease-activated receptor 2 (PAR2) agonist.
-
A8670
AC 264613
Potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 7.5).
-
A8669
AC 55541
Potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 6.7) that displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation.
